Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase
- 1 March 2002
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 9 (3), 236-242
- https://doi.org/10.1038/sj.cgt.7700440
Abstract
There are at least two hurdles confronting the use of the adenovirus (Ad)-mediated herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) system for the treatment of cancer. One is inefficient Ad vector–mediated gene transfer into tumor cells lacking the primary receptor, i.e., the coxsackievirus and adenovirus receptor (CAR). The other is hepatotoxicity due to unwanted vector spread into the liver, even when Ad vectors are injected intratumorally. Herein, we present an attractive strategy for overcoming such limitations based on use of a fiber-modified Ad vector containing an RGD peptide motif in the fiber knob. HSVtk-expressing Ad vectors containing mutant fiber (AdRGD-tk) or wild-type fiber (Ad-tk) were injected intratumorally into CAR-negative B16 melanoma cells inoculated into mice, after which GCV was injected intraperitoneally for 10 days. AdRGD-tk showed approximately 25 times more antitumor activity than Ad-tk. Histopathological studies suggested that liver damage in mice injected with AdRGD-tk was significantly lower than that in mice injected with Ad-tk. Intratumoral administration of luciferase-expressing Ad vectors containing the mutant fiber (AdRGD-L2) resulted in nearly 40 times more luciferase production in the tumor, but 8 times less production in the liver than the conventional Ad vectors (Ad-L2). These results indicate that combination of fiber-modified vectors and a HSVtk/GCV system is a potentially useful and safe approach for the treatment of tumors lacking CAR expression, and that fiber-modified vectors could be of great utility for gene therapy and gene transfer experiments.Keywords
This publication has 33 references indexed in Scilit:
- Adenoviral-Mediated Gene Therapy for Thyroid Carcinoma Using Thymidine Kinase Controlled by Thyroglobulin Promoter Demonstrates High Specificity and Low ToxicityThyroid®, 2001
- Transduction of a Fiber-mutant Adenovirus for theHSVtkGene Highly Augments the Cytopathic Effect towards GliomasJapanese Journal of Cancer Research, 2000
- Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptorJournal of Neurosurgery, 2000
- Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: The woodchuck animal modelCancer Gene Therapy, 2000
- A Simple Method for Constructing E1- and E1/E4-Deleted Recombinant Adenoviral VectorsHuman Gene Therapy, 1999
- Efficient Construction of a Recombinant Adenovirus Vector by an ImprovedIn VitroLigation MethodHuman Gene Therapy, 1998
- Preclinical Testing of Recombinant Adenoviral Herpes Simplex Virus-Thymidine Kinase Gene Therapy for Central Nervous System MalignanciesNeurosurgery, 1997
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- Safety of Intrapleurally Administered Recombinant Adenovirus Carrying Herpes Simplex Thymidine Kinase DNA Followed by Ganciclovir Therapy in Nonhuman PrimatesHuman Gene Therapy, 1996
- Herpes Simplex Virus Thymidine Kinase Gene Therapy for Rat Malignant Brain TumorsHuman Gene Therapy, 1996